277 related articles for article (PubMed ID: 22352336)
21. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team
HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092
[TBL] [Abstract][Full Text] [Related]
22. Randomized trial to evaluate cardiometabolic and endothelial function in patients with plasma HIV-1 RNA suppression switching to darunavir/ritonavir with or without nucleoside analogues.
Guaraldi G; Zona S; Cossarizza A; Vernacotola L; Carli F; Lattanzi A; Beghetto B; Orlando G; De Biasi S; Termini R; Garau M
HIV Clin Trials; 2013; 14(4):140-8. PubMed ID: 23924586
[TBL] [Abstract][Full Text] [Related]
23. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
[TBL] [Abstract][Full Text] [Related]
24. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
[TBL] [Abstract][Full Text] [Related]
25. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
Dejesus E; Mills A; Bhatti L; Conner C; Storfer S
Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631
[TBL] [Abstract][Full Text] [Related]
26. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Dierynck I; De Meyer S; Lathouwers E; Vanden Abeele C; Van De Casteele T; Spinosa-Guzman S; de Béthune MP; Picchio G
Antivir Ther; 2010; 15(8):1161-9. PubMed ID: 21149923
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population.
Rusconi S; Giacomet V; Mameli C; Viganò A; Viganò O; Adorni F; Galli M; Zuccotti GV
BMC Infect Dis; 2012 Aug; 12():179. PubMed ID: 22866946
[TBL] [Abstract][Full Text] [Related]
28. Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
Taiwo B; Acosta EP; Ryscavage P; Berzins B; Lu D; Lalezari J; Castro J; Adeyemi O; Kuritzkes DR; Eron JJ; Tsibris A; Swindells S
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):167-73. PubMed ID: 23797691
[TBL] [Abstract][Full Text] [Related]
29. A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.
Ofotokun I; Sheth AN; Sanford SE; Easley KA; Shenvi N; White K; Eaton ME; Del Rio C; Lennox JL
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1196-206. PubMed ID: 22364141
[TBL] [Abstract][Full Text] [Related]
30. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
[TBL] [Abstract][Full Text] [Related]
31. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
Moltó J; Valle M; Santos JR; Mothe B; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Barbanoj MJ; Clotet B
Antivir Ther; 2010; 15(2):219-25. PubMed ID: 20386077
[TBL] [Abstract][Full Text] [Related]
32. Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice.
Antoniou T; Raboud JM; Diong C; Su D; Dewhurst N; Buckley V; Kovacs C; Rachlis A; Brunetta J; Smith G; Gough K; Fletcher D; Loutfy MR
J Int Assoc Physicians AIDS Care (Chic); 2010; 9(6):382-9. PubMed ID: 21138833
[TBL] [Abstract][Full Text] [Related]
33. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
Wohl DA; Bhatti L; Small CB; Edelstein H; Zhao HH; Margolis DA; DeJesus E; Weinberg WG; Ross LL; Shaefer MS
HIV Med; 2016 Feb; 17(2):106-17. PubMed ID: 26176344
[TBL] [Abstract][Full Text] [Related]
34. Atazanavir: in pediatric patients with HIV-1 infection.
Deeks ED
Paediatr Drugs; 2012 Apr; 14(2):131-41. PubMed ID: 22292486
[TBL] [Abstract][Full Text] [Related]
35. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.
Sekar V; Lefebvre E; De Marez T; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
Clin Drug Investig; 2008; 28(8):479-85. PubMed ID: 18598093
[TBL] [Abstract][Full Text] [Related]
36. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
Vrouenraets SM; Wit FW; Fernandez Garcia E; Moyle GJ; Jackson AG; Allavena C; Raffi F; Jayaweera DT; Mauss S; Katlama C; Fisher M; Slama L; Hardy WD; Dejesus E; van Eeden A; Reiss P;
HIV Med; 2011 Nov; 12(10):620-31. PubMed ID: 21819530
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D
Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732
[TBL] [Abstract][Full Text] [Related]
38. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.
Murphy RL; Berzins B; Zala C; Fichtenbaum C; Dube MP; Guaraldi G; Torriani F; Belsey E; Mitchell C; Stein JH;
AIDS; 2010 Mar; 24(6):885-90. PubMed ID: 19952712
[TBL] [Abstract][Full Text] [Related]
39. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
Brogan A; Mauskopf J; Talbird SE; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
[TBL] [Abstract][Full Text] [Related]
40. Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.
Delille CA; Pruett ST; Marconi VC; Lennox JL; Armstrong WS; Arrendale RF; Sheth AN; Easley KA; Acosta EP; Vunnava A; Ofotokun I
J Clin Pharmacol; 2014 Sep; 54(9):1063-71. PubMed ID: 24691856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
